[1]葛乃建,杨业发.再论肝癌TACE与HAIC的联合临床应用[J].介入放射学杂志,2025,34(02):129-133.
　GE Naijian,YANG Yefa..A further discussion on the clinical application of TACE and HAIC for hepatocellular carcinoma[J].journal interventional radiology,2025,34(02):129-133.
点击复制

再论肝癌TACE与HAIC的联合临床应用()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
34
期数:
2025年02
页码:
129-133
栏目:
专论
出版日期:
2025-02-17

文章信息/Info

Title:
A further discussion on the clinical application of TACE and HAIC for hepatocellular carcinoma
作者:
葛乃建; 杨业发
Author(s):
GE Naijian; YANG Yefa.
Department of Interventional Radiology，Shanghai Eastern Hepatobiliary Surgery Hospital，Third Affiliated Hospital of Naval Medical University，Shanghai 200438，China
关键词:
【关键词】肝动脉灌注化疗; 经动脉化疗栓塞术; 肝细胞癌; 肝动脉灌注化疗与经动脉化疗栓塞联用
文献标志码:
A
摘要:
【摘要】经动脉化疗栓塞术（TACE）是公认的肝癌非手术切除的首选治疗方式，而肝动脉灌注化疗术（hepatic artery infusion chemotherapy，HAIC）是另一种有效的介入方法。两者用于治疗肝癌的研究众多，也引起了医学界广泛的争论。将肝癌HAIC与TACE的合理联用定义为灌注TACE（iTACE，infusion transarterial chemoembolization）。该文从iTACE的概念、应用方法、适应证和禁忌证、疗效与不良反应、联合靶向免疫等方面进行介绍，期望有助于临床的推广应用。

参考文献/References:

［1］中华人民共和国国家卫生健康委员会.原发性肝癌诊疗指南（2024年版）［J］.磁共振成像，2024，15：1-18.
［2］中国抗癌协会肝癌专业委员会.肝动脉灌注化疗治疗肝细胞癌中国专家共识（2021版）［J］.中华消化外科杂志，2021，20：754-759.
［3］Ge N，Wang H，He C，et al.Optimal interventional treatment for liver cancer：HAIC，TACE or iTACE?［J］.J Interv Med，2023，6：59-63.
［4］Irie T，Kuramochi M，Takahashi N.Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization：measurement of balloon-occluded arterial stump pressure［J］.Cardiovasc Intervent Radiol，2013，36：706-713.
［5］Hochster HS，Green MD，Speyer J，et al.4′Epidoxorubicin （epirubicin）：activity in hepatocellular carcinoma［J］.J Clin Oncol，1985，3：1535-1540.
［6］Itamoto T，Nakahara H，Tashiro H，et al.Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein［J］.J Surg Oncol，2002，80：143-148.
［7］Lyu N，Lin Y，Kong Y，et al.FOXAI：a phase Ⅱ trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma［J］.Gut，2018，67：395-396.
［8］张雯，周永杰，颜志平.再论精细TACE［J］.介入放射学杂志，2021，30：971-975.
［9］Llovet J，Ricci S，Mazzaferro V，et al.Sorafenib in advanced hepatocellular carcinoma［J］.N Engl J Med，2008，359：378-390.
［10］Li QJ，He MK，Chen HW，et al.Hepatic arterial infusion of oxaliplatin，fluorouracil，and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma：a randomized phase Ⅲ trial［J］.J Clin Oncol，2022，40：150-160.
［11］Zhang B，Huang B，Yang F，et al.High-risk hepatocellular carcinoma：hepatic arterial infusion chemotherapy versus transarterial chemoembolization［J］.J Hepatocell Carcinoma，2024，11：651-663.
［12］Aramaki O，Takayama T，Moriguchi M，et al.Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma （ACE 500 study）：a multicentre，randomised controlled phase 2/3 trial［J］.Eur J Cancer，2021，157：373-382.
［13］Ogasawara S，Chiba T，Ooka Y，et al.A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization［J］.Hepatology，2018，67：575-585.
［14］Wang L，Hu X，Shen X，et al.Intraarterial lidocaine administration for pain control by water-in-oil technique in transarterial chemoembolization：in vivo and randomized clinical trial［J］.J Hepatocell Carcinoma，2021，8：1221-1232.
［15］高嵩，朱旭，杨仁杰，等.TACE联合奥沙利铂、氟尿嘧啶、亚叶酸钙肝动脉化疗治疗中晚期原发性肝癌［J］.介入放射学杂志，2012，21：377-383.
［16］Yang J，Shang X，Li J，et al.Comparative study on the efficacy and safety of transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for large unresectable hepatocellular carcinoma［J］.J Gastrointest Oncol，2024，15：346-355.
［17］Guo W，Gao J，Zhuang W，et al.Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma：a propensity score-matching cohort study［J］.JGH Open，2020，4：477--483.
［18］Gao S，Zhang P，Guo J，et al.Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients［J］.World J Gastroenterol，2015，21：10443-10452.
［19］Li B，Qiu J，Zheng Y，et al.Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma［J］.Ann Surg Open，2021，2：e057.
［20］Li J.Effect ofwarming yang，tonifying kidney，and removing arthralgia therapy on cold-dampness arthralgia type ankylosing spondylitis and its influence on the levels of humoral factor in human serum［J］.Biomed Res Int，2022，2022：8348272.
［21］陈嵩，吴志强，庄文权，等.经肝动脉栓塞术联合FOLFOX4方案持续动脉灌注化疗治疗肝细胞癌合并门静脉癌栓15例近期临床疗效评价［J］.介入放射学杂志，2019，28：328-333.
［22］Huang J，Huang W，Zhan M，et al.Drug-eluting bead transarterial chemoembolization combined with FOLFOX-based hepatic arterial infusion chemotherapy for large or huge hepatocellular carcinoma［J］.J Hepatocell Carcinoma，2021，8：1445-1458.
［23］Liu B，Gao S，Guo J，et al.Efficacy and safety of hepasphere drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy as the second-line treatment in advanced hepatocellular Carcinoma［J］.J Hepatocell Carcinoma，2024，11：477-488.
［24］马洺远，黄利生，林纲毅，等.持续经肝动脉灌注联合栓塞治疗胃癌肝转移的临床疗效和安全性评价［J］.临床医学工程，2020，27：765-766.
［25］Zhang H，Guo J，Gao S，et al.Prognostic factors for transarterial chemoembolization combined with sustained oxaliplatin-based hepatic arterial infusion chemotherapy of colorectal cancer liver metastasis［J］.Chin J Cancer Res，2017，29：36-44.
［26］Reig M，Forner A，Rimola J，et al.BCLC strategy for prognosis prediction and treatment recommendation：the 2022 update［J］.J Hepatol，2022，76：681-693.
［27］黄剑，葛乃建，徐伟，等.TACE联合卡瑞利珠单抗及甲磺酸阿帕替尼治疗晚期肝细胞癌16例［J］.介入放射学杂志，2021，30：774-779.
［28］王宏博，刘福晨，刘辉，等.经肝动脉化疗栓塞术联合多纳非尼与替雷利珠单抗治疗中晚期肝癌34例［J］.临床放射学杂志，2024，43：443-449.
［29］Zhu H，Li H，Huang M，et al.Transarterial chemoembolization with PD-（L）1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma （CHANCE001）［J］.Signal Transduct Target Ther，2023，8：58.
［30］Jin Z，Chen J，Zhu X，et al.Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma （CHANCE2201）：a target trial emulation study［J］.E Clinical Medicine，2024，72：102622.
［31］Meric-Bernstam F，Makker V，Oaknin A，et al.Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors：Primary results from the DESTINY-pantumor02 phase Ⅱ trial［J］.J Clin Oncol，2024，42：47-58.
［32］Huang Z，Wu Z，Zhang L，et al.The safety and efficacy of TACE combined with HAIC，PD-1 inhibitors，and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma：a retrospective study［J］.Front Oncol，2024，14：1298122.
［33］Zhao W，Liu C，Wu Y，et al.Transarterial chemoembolization （TACE）-hepatic arterial infusion chemotherapy （HAIC） combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma：a single center experience［J］.Transl Cancer Res，2024，13：2315-2331.
［34］Liu B，Gao S，Guo J，et al.A novel nomogram for predicting the overall survival in patients with unresectable HCC after TACE plus hepatic arterial infusion chemotherapy［J］.Transl Oncol，2023，34：101705.

相似文献/References:

[1]蔡丽霞,张岳林,孙军辉.新型冠状病毒肺炎期间介入手术患者整体护理策略 [J].介入放射学杂志,2020,29(03):315.
　CAI Lixia,ZHANG Yuelin,SUN Junhui..Nursing strategy for patients receiving interventional therapy during the epidemic outbreak period of novel coronavirus pneumonia[J].journal interventional radiology,2020,29(02):315.
[2]王天成,马聪,肖煜东,等.利多卡因-表阿霉素-超液化碘油混合乳剂在肝癌TACE相关疼痛管理中的应用 [J].介入放射学杂志,2020,29(04):366.
　WANG Tiancheng,MA Cong,XIAO Yudong,et al.The application of lidocaine-epirubicin-lipiodol emulsion in the management of TACE-related pain in HCC patients[J].journal interventional radiology,2020,29(02):366.
[3]纪坤,李臻,李鑫,等.载药微球化疗栓塞治疗巨大扁桃体鳞癌1例 [J].介入放射学杂志,2020,29(02):219.
　JI Kun,LI Zhen,LI Xin,et al.Successful treatment of giant tonsillar squamous cell carcinoma with chemoembolization by using drug-eluting beads: report of one case[J].journal interventional radiology,2020,29(02):219.
[4]方主亭,张 雯,马婧嵚,等.血管内近程放疗在肝癌合并门静脉一级分支癌栓中的应用[J].介入放射学杂志,2021,30(01):74.
　FANG Zhuting,ZHANG Wen,MA Jinqin,et al.Application of endovascular brachytherapy combined with transcatheter arterial chemoembolization in treating hepatocellular carcinoma associated with tumor thrombus in the first- order branch of portal vein[J].journal interventional radiology,2021,30(02):74.
[5]仲斌演,王万胜,张 申,等.TACE抵抗的重新认知：一项中国医师协会介入医师分会发起的调查研究[J].介入放射学杂志,2023,32(07):642.
　ZHONG Binyan,WANG Wansheng,ZHANG Shen,et al.Re-understanding of TACE failure/refractoriness： a survey initiated by the Chinese College of Interventionalists[J].journal interventional radiology,2023,32(02):642.

备注/Memo

备注/Memo:
（收稿日期：2024-08-29）
（本文编辑：新宇）
更新日期/Last Update: 2025-02-17